Effect of icosapent ethyl on coronary Fat Attenuation Index score in high-risk, statin treated patients with established cardiovascular disease and elevated plasma triglycerides

Start Date26 Mar 2025

Sponsor / Collaborator

Imperial College London

NCT06710080

/ Not yet recruitingPhase 3IIT

Targeting Vascular INflammation in Patients with Community-Acquired Pneumonia (TIN_CAP): a Multi-centre, Prospective, Randomized Control Trial

The goal of this clinical trial is to learn if icosapent ethyl (Vascepa) works to lessen the amount of inflammation in adults diagnosed with Community-Acquired Pneumonia (CAP). The main question it aims to answer is:
What is the effect of taking Vascepa on inflammation in the arteries in patients with CAP? Researchers will compare the drug Vascepa to a placebo (a look-alike submstance that contains no drug) to see if Vascepa works to reduce inflammation in patients with CAP.
Participants wil:
* take Vacscepa or a placebo twice a day for 6 months
* Visit the clinic 3 times (baseline, 30 days, and 6 months) for checkups and tests

Start Date15 Dec 2024

Sponsor / Collaborator

Ottawa Heart Institute Research Corp.

ISRCTN64669648

/ RecruitingNot ApplicableIIT

Does Vazkepa mitigate the negative effects of metabolic memory in monocyte-derived macrophages isolated from patients with cardiovascular disease +/- type 2 diabetes?

Start Date26 Apr 2024

Sponsor / Collaborator

The University of Lincoln

100 Clinical Results associated with Icosapent Ethyl

100 Translational Medicine associated with Icosapent Ethyl

100 Patents (Medical) associated with Icosapent Ethyl

1,036

Literatures (Medical) associated with Icosapent Ethyl

01 Dec 2025·INTERNATIONAL JOURNAL OF CARDIOLOGY

Eligibility for icosapent ethyl 1–3 months after acute coronary syndrome and the risk for myocardial re-infarction: Data from the CALLINICUS-Hellas Registry

Article

Author: Makridakis, Nikolaos ; Leventis, Ioannis ; Vlachopoulos, Charalambos ; Bouratzis, Vasileios ; Nastatos, Panagiotis ; Tsamoulis, Donatos ; Ntalaoutis, Andreas ; Xanthopoulou, Sofia ; Kyriazis, Michalis ; Stamou, Ilektra ; Daios, Stylianos ; Kakouri, Niki ; Rallidis, Loukianos S ; Argyriou, Nikos ; Papathanasiou, Konstantinos A ; Boulmpou, Aristi ; Afentoulis, Vasilis ; Gaitanaki, Tsampika ; Malkots, Belkis ; Styliaras, Athanasios ; Kalogeras, Petros ; Roussos, Christos

BACKGROUND:

Icosapent ethyl (IPE) has been shown to reduce adverse cardiovascular (CV) outcomes in high or very high-risk patients on statins with triglyceride (TG) levels between 135 and 499 mg/dL METHODS: The CALLINICUS-Hellas registry is an ongoing, prospective, multicenter study evaluating lipid profiles, adherence to lipid-lowering therapies, and prognosis in acute coronary syndrome (ACS) patients. This analysis included patients with lipids assessed 4-12 weeks post-ACS who were divided into two groups: Those eligible for IPE administration according to the 2019 ESC/EAS guidelines for the Management of Dyslipidaemias and those not eligible. Cardiometabolic profile at discharge and the incidence of 3-point major adverse CV events [3P-MACE; non-fatal myocardial infarction (MI), non-fatal stroke, cardiac death] within 12 months were compared between groups RESULTS: A total of 1254 patients had their lipid profile evaluated 4-12 weeks post-discharge and the vast majority (97.1 %) were on statins. Of those, 25.6 % were eligible for IPE administration while among patients with diabetes mellitus (DM) the eligibility was higher (32.6 %). IPE-eligibility was associated with an adverse cardiometabolic profile (higher prevalence of DM, hypertension, obesity and atherogenic dyslipidemia) and an increased risk of non-fatal MI within 12 months (5.9 % vs. 3.1 %, p = 0.027), even after adjustment for potential confounders. Rates of 3P-MACE, non-fatal stroke and cardiac death were similar between subgroups CONCLUSION: Approximately 1 in 4 post-ACS patients fulfill IPE-eligibility criteria and face an increased risk of myocardial reinfarction within 12 months. Early administration of IPE may play an essential role in mitigating residual CV risk detected by high TGs.

01 Dec 2025·AMERICAN HEART JOURNAL

Utilization and spending on lipid lowering therapies in medicaid from 2018 to 2022

Article

Author: Wadhera, Rishi K ; Beschloss, Alexander ; Oseran, Andrew S

BACKGROUND:

To determine how utilization and spending on lipid lowering medications in Medicaid changed between 2018 and 2022.

METHODS:

Retrospective, cross-sectional study of utilization and spending on 32 lipid lowering drug formulations (18 brand-name, 14 generic) using the Medicaid Spending by Drug Dataset (2018-2022).

RESULTS:

The study included over 115 million prescription fills in the Medicaid program. Between 2018 and 2022, annual prescription fills for lipid lowering medications increased 1.2%, from 22.7 million per year to 22.9 million per year, while annual Medicaid spending on these medications increased 13.2%, from $348.3 million to $394.4 million per year. Annual statin utilization remained stable over the study period (20.4 million fills in 2018 compared to 20.3 million fills in 2022), while spending on statins decreased (from $243.9 million to $228.3 million). Conversely, annual prescription fills and spending for PCSK9 inhibitors (7,617 fills and $8.9 million to 121,737 fills and $65.7 million), icosapent ethyl (32,527 fills and $10.2 million to 180,291 fills and $50.2 million), and bempedoic acid (from 494 fills and $215,499 to 4,619 fills and $2.2 million) all increased between 2018 and 2022.

CONCLUSION:

Between 2018 and 2022, annual prescription fills for lipid lowering therapies in Medicaid remained stable while spending on these medications increased, driven by increased utilization of PCSK9 inhibitors, icosapent ethyl, and bempedoic acid. As Medicaid budgets face escalating financial pressure-and the burden of cardiovascular disease increases among low-income adults in Medicaid-it is critical that policymakers continue to monitor utilization and spending on existing and novel high-cost medical therapies.

01 Sep 2025·Comparative Biochemistry and Physiology D-Genomics & Proteomics

α-Ketoglutarate modulates the mechanisms of toxicity in crucian carp kidneys chronically exposed to NaHCO3: Metabolomics insights

Article

Author: Han, Lin ; Yuan, Fangying ; Liu, Wenzhi ; Liu, Qianwen ; Jin, Xiaofeng ; Cheng, Hongyu ; Sun, Yanchun

Due to the unique physicochemical properties of saline-alkaline water, aquatic organisms find it challenging to survive under such conditions. This study established a freshwater control group (C), a 20 mmol/L NaHCO₃ exposure group (T), a 40 mmol/L NaHCO₃ exposure group (F), a 20 mmol/L NaHCO₃ exposure with α-ketoglutarate (AKG)-supplemented feed group (TA), and a 40 mmol/L NaHCO₃ exposure with AKG-supplemented feed group (FA). Histopathological analysis, biochemical assays, and UPLC-QTOF/MS metabolomics were employed to explore the potential mechanisms by which AKG alleviates oxidative damage in freshwater teleosts induced by saline-alkaline stress. Histopathological results showed that as the concentration of carbonate alkali exposure increased, the severity of kidney lesions in crucian carp (Carassius auratus) worsened. However, in the TA and FA groups, the damage showed varying degrees of repair, with the kidney tissue morphology in the TA group almost restored to the state of the C group. Under carbonate alkali exposure, compared to the C group, the activity of antioxidant enzymes Catalase and Superoxide dismutase in crucian carp kidneys decreased in a dose-dependent manner, but increased upon AKG supplementation. Conversely, the levels of Malondialdehyde, blood ammonia, Urea nitrogen, and Uric acid showed the opposite trend. Metabolomics analysis revealed that carbonate-alkali stress caused a series of metabolic disruptions in fish, including amino acid metabolism, lipid metabolism, and energy metabolism. AKG positively regulated metabolic pathways such as the pentose phosphate pathway, arachidonic acid metabolism, and amino acid metabolism, thereby enhancing the antioxidant, anti-inflammatory, and immune capabilities of fish under saline-alkaline stress, alleviating oxidative damage induced by the stress. Overall, our research indicates that saline-alkaline stress significantly alters kidney function and metabolic characteristics, disrupts the antioxidant system and energy homeostasis, inhibits protein catabolism, and induces kidney damage in crucian carp. Exogenous AKG supplementation effectively mitigates oxidative damage and metabolic disorders in crucian carp kidneys under carbonate-alkaline stress. This study elucidates the physiological mechanisms by which AKG alleviates kidney tissue damage under saline-alkaline stress at the metabolic level, providing scientific evidence for the development of aquaculture in saline-alkaline water.

149

News (Medical) associated with Icosapent Ethyl

02 Jul 2025

·hlstherapeutics.com

HLS Therapeutics Announces Reimbursement for Vascepa® under Nova Scotia's Provincial Drug Plan

Vascepa is now available to more than 95% of Canadians who are eligible and covered by a public plan or private insurance TORONTO, July 2, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that it has entered into a Product Listing Agreement ("PLA") with the province of Nova Scotia, for the listing and public reimbursement of Vascepa (icosapent ethyl). The PLA with Nova Scotia Pharmacare is effective July 1, 2025. Under the terms of the PLA, Vascepa will be reimbursed as an exception status product by the Nova Scotia formulary for the secondary prevention of cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization or hospitalization for unstable angina) in statin-treated patients with established cardiovascular disease and elevated triglycerides. "The PLA with Nova Scotia Pharmacare will significantly improve access and reimbursement for Vascepa in Atlantic Canada," said Craig Millian, CEO of HLS. "This milestone, combined with the recent in-licensing of two new products into our cardiovascular portfolio, supports our efforts to position HLS as a leading Canadian-based company focused on reducing cardiovascular risk for Canadians." Vascepa is now available to more than 95% of eligible patients covered by public plans and private insurance in Canada. ABOUT VASCEPA (ICOSAPENT ETHYL) CAPSULES Vascepa capsules are the first-and-only prescription treatment comprised solely of the active ingredient, icosapent ethyl (IPE), a unique form of eicosapentaenoic acid. Vascepa was approved by Health Canada and added to Health Canada's Register of Innovative Drugs and benefits from data protection for a term of eight years, as well as being the subject of multiple issued and pending patents based on its unique clinical profile. HLS in-licensed the exclusive rights to Vascepa for the Canadian market from Amarin Corporation (NASDAQ:AMRN). ABOUT HLS THERAPEUTICS INC. Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit: www.hlstherapeutics.com FORWARD LOOKING INFORMATION This release includes forward-looking statements regarding HLS and its business. Such statements are based on the current expectations and views of future events of HLS's management. In some cases the forward-looking statements can be identified by words or phrases such as "may", "will", "expect", "plan", "anticipate", "intend", "potential", "estimate", "believe" or the negative of these terms, or other similar expressions intended to identify forward-looking statements, including, among others, statements with respect to HLS's pursuit of additional product and pipeline opportunities in certain therapeutic markets, statements regarding growth opportunities and expectations regarding financial performance. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting HLS, including risks relating to the specialty pharmaceutical industry, risks related to the regulatory approval process, economic factors and many other factors beyond the control of HLS. Forward-looking statements and information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause HLS's actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statement or information. Accordingly, readers should not place undue reliance on any forward-looking statements or information. A discussion of the material risks and assumptions associated with this release can be found in the Company's Annual Information Form dated March 12, 2025, and Management's Discussion and Analysis dated May 7, 2025, both of which have been filed on SEDAR+ and can be accessed at www.sedarplus.ca. Accordingly, readers should not place undue reliance on any forward-looking statements or information. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and HLS undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. SOURCE HLS Therapeutics Inc.

Drug Approval

24 Jun 2025

·www.fiercepharma.com

Amarin sells heart pill Vascepa's rights in Europe to Recordati amid restructuring bid

Paying $25 million upfront and potential milestones of $150 million, Recordati will take over commercialization of Amarin's heart-helping drug Vascepa in Europe. With sales of its lone product in a precipitous decline in the United States, Amarin has turned to an experienced local partner to boost them in Europe.Amarin has forged a licensing deal with Italian pharma Recordati to commercialize its fish oil-derived heart pill Vascepa in Europe, where the drug is known as Vazkepa. Recordati will pay $25 million upfront to market the product to 59 European countries. Recordati also is on the hook for $150 million in potential milestone payments, tied to specific annual sales targets, and for supply-based royalties.With the move, Amarin's share price increased by 31%.Amarin’s sales of Vascepa have plummeted since it caved to generic competition in the U.S. in 2020, just three months after the FDA granted it what seemed to be a game-changing label expansion to reduce cardiovascular risks. After Amarin’s revenue peaked at $614 million in 2020, it has fallen every year since. In 2024, the company reported sales of $229 million.With Vazkepa’s patent protection in place in Europe until 2039, Amarin believes the product still can thrive with the help of an established partner. Amarin has been marketing Vazkepa as a treatment added to statins for patients who are at risk of a cardiovascular event.“We know from our experience, in particular from the U.S., and from the clinical profile of Vazkepa, that there is significant opportunity or growth because of the unmet need (in Europe),” Amarin CEO Aaron Berg said during a conference call on Tuesday.Over the last few years, Amarin has attempted to build a market in Europe but with little success. In the fourth quarter of last year, the company reported just $4 million of its $62 million revenue from Europe.“Even the biggest companies are challenged launching products in European countries,” Berg said. “It’s particularly difficult for a one-product company with no established infrastructure to start and build from scratch. It’s a long-term endeavor. This product has significant potential. But that also means it takes significant resources over a period of time.” The partnership will allow Amarin to “streamline its global operations, which further strengthens the Company’s financial position,” it said in the release.In addition, in the statement, the chairman of Amarin’s board, Odysseas Kostas, M.D., cited Recordati’s “experience in the cardiovascular space in Europe.” The company, which celebrates its 100th birthday next year, derives roughly 25% of its revenue from its cardiovascular portfolio. With the move, Amarin said it will save $70 million over the next 12 months. The company touted its “financial strength,” as it has nearly $300 million in cash and no debt, it said.“We’re sharpening our operational focus by restructuring the organization, which positions the company for greater future financial performance,” Berg said. “We continue to act in a proactive and decisive manner to identify and pursue additional strategic opportunities to drive shareholder value. Nothing is off the table.”

License out/inDrug Approval

24 Jun 2025

·www.globenewswire.com

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE Vazkepa® supported by strong clinical data package and expected to contribute to Specialty & Primary Care growth in coming years Milan, 24 June 2025 – Recordati today announced a licensing and supply agreement with Amarin to commercialize the marketed cardiovascular medicine, Vazkepa® (icosapent ethyl) across 59 countries, focused in Europe. Vazkepa® is indicated to reduce the risk of cardiovascular events in statin-treated adult patients at high cardiovascular risk with elevated triglycerides and either established cardiovascular disease or diabetes with at least one other cardiovascular risk factor. Vazkepa® was approved in 2021 in the EU and UK and in 2022 in Switzerland based on the REDUCE-IT study, a Phase 3 Cardiovascular Outcomes Trial (CVOT) performed in over 8,000 patients with statistically significant and clinically meaningful results in Major Adverse Cardiovascular Events (MACE). Vazkepa® is the only treatment option that has effectively reduced cardiovascular risk in statin-treated patients with elevated or high triglycerides in a Cardiovascular Outcomes Trial and has been incorporated as a therapeutic option within multiple treatment guidelines and scientific statements due to its robust clinical data package. Vazkepa® has patent protection in Europe up to 2039. Vazkepa® is currently commercialized in 11 European countries, generating net sales of € 12 million in 2024 and is expected to achieve over € 40 million in revenues in 2027 and to be EBITDA positive from 2026. Under the terms of the agreement, Recordati will pay Amarin an upfront cash payment of US$ 25 million. Amarin will supply finished product to Recordati and is eligible to receive royalties for the supply of the product under the terms of the agreement and commercial milestones up to a total of US$ 150 million if annual revenues for Vazkepa® in the territories in scope exceed certain sales thresholds starting from € 100 million. More details will be provided during the first half 2025 conference call on July 30th. Rob Koremans, Chief Executive Officer, Recordati, commented, “We are extremely pleased with the agreement with Amarin for Vazkepa® which underscores our deep expertise in the Cardiovascular space and our ongoing commitment to continue strengthening our Specialty & Primary Care business with innovative medicines in our core therapeutic areas. Vazkepa® is a best-in-class treatment option that complements our existing portfolio, is supported by a robust clinical data package, has the ability to make a meaningful impact for cardiovascular patients and contribute to the growth of Specialty & Primary Care for years to come." Alberto Martinez, EVP, Specialty & Primary Care: “Vazkepa® complements our portfolio well. Supported by strong science, growing medical advocacy, and recently granted patent protection extending the exclusivity in Europe up to 2039, Vazkepa® has a long runway to make a meaningful impact for millions of cardiovascular patients. We are confident that together we can deliver accelerated growth in Europe and significant value for both Amarin and all stakeholders of Recordati.” Aaron Berg, President & CEO of Amarin, added, “Recordati is a successful, well-established partner uniquely positioned to maximize the commercial opportunity for VAZKEPA. We are confident in Recordati’s ability to lead the next phase of growth and impact patient care with VAZKEPA throughout Europe.” Recordati is an international pharmaceutical group listed on the Italian Stock Exchange (XMIL: REC), with roots dating back to a family-run pharmacy in Northern Italy in the 1920s. We are uniquely structured to provide treatments across specialty and primary care, and rare diseases. Our fully integrated operations span clinical development, chemical and finished product manufacturing, commercialization and licensing. We operate in approximately 150 countries across EMEA, the Americas and APAC with over 4,450 employees. We believe that health is a fundamental right, not a privilege. Today, our purpose of “unlocking the full potential of life” aims at empowering individuals to live life to the fullest, whether addressing common health challenges or the rarest. Investor Relations Eugenia Litz +44 7824 394 750 investorelations@recordati.itGianluca Saletta +39 348 979 4876 investorelations@recordati.itMedia Relations ICR Healthcare US:Alexis Feinberg +1 203 939 2225 Alexis.feinberg@icrhealthcare.com UK, Europe & Rest of World:Jessica Hodgson +44 7561 424 788jessica.hodgson@icrhealthcare.com This document contains forward-looking statements relating to future events and future operating, economic and financial results of the Recordati group. By their nature, forward-looking statements involve risk and uncertainty because they depend on the occurrence of future events and circumstances. Actual results may therefore differ materially from those forecast as a result of a variety of reasons, most of which are beyond the Recordati group’s control. The information on the pharmaceutical specialties and other products of the Recordati group contained in this document is intended solely as information on the activities of the Recordati Group, and, as such, it is not intended as a medical scientific indication or recommendation, or as advertising.

Phase 3Drug ApprovalLicense out/inAHA

100 Deals associated with Icosapent Ethyl

External Link

KEGG	Wiki	ATC	Drug Bank
D01892	Icosapent Ethyl	C10AX	DB08887

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus	South Korea	Alvogen Korea Co., Ltd.	22 May 2025
Pain	South Korea	RP Bio, lnc.	21 Feb 2022
Ulcer	South Korea	RP Bio, lnc.	21 Feb 2022
Cardiovascular Diseases	United States	Amarin Pharmaceuticals Ireland Ltd.	13 Dec 2019
Hypertriglyceridemia	United States	Amarin Pharmaceuticals Ireland Ltd.	26 Jul 2012
Arteriosclerosis Obliterans	Japan	Mochida Pharmaceutical Co., Ltd.	15 Oct 1998
Hyperlipidemias	Japan	Mochida Pharmaceutical Co., Ltd.	05 Oct 1994

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Colonic Cancer	Phase 3	United Kingdom	Amarin Pharma, Inc.	02 May 2018
Liver metastases	Phase 3	United Kingdom	Amarin Pharma, Inc.	02 May 2018
Huntington Disease	Phase 3	United States	Amarin Neuroscience Ltd.	01 Sep 2005
Huntington Disease	Phase 3	Canada	Amarin Neuroscience Ltd.	01 Sep 2005
Nonalcoholic Steatohepatitis	Phase 2	United States	Mochida Pharmaceutical Co., Ltd.	01 Jun 2010
Nonalcoholic Steatohepatitis	Phase 2	Puerto Rico	Mochida Pharmaceutical Co., Ltd.	01 Jun 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01492361 (REDUCE-IT, Pubmed \| J Am Heart Assoc) Manual	Phase 3	Cardiovascular Diseases LDL-C	8,175	Icosapent Ethyl 2g twice dailyIcosapent Ethyl 2g twice daily (LDL‐C <55 mg/dL)	dwoxbgrenp(pewhilmeom) = cwukbnqfcp dgwdfhdihy (bfnfynlxmw )	Positive	19 Feb 2025
				Placebo (LDL‐C <55 mg/dL)	dwoxbgrenp(pewhilmeom) = szyacooahu dgwdfhdihy (bfnfynlxmw )
NCT02719327 (BRAVE-EPA, CTgov)	Phase 2/3	Alzheimer Disease	131	icosapent ethyl (Icosapent Ethyl (IPE))	samrgrctnc(ydbhagylnl) = xgxptezwln kyodrlfzrz (hrmtkcwqob, 14.6) View more	-	26 Nov 2024
				gel cap placebo (Placebo)	samrgrctnc(ydbhagylnl) = alahlnskis kyodrlfzrz (hrmtkcwqob, 14.1) View more
NCT05198843 (CTgov)	Phase 1/2	Metastatic breast cancer \| Metastatic Triple-Negative Breast Carcinoma	1	Dasatinib+EPA	fvpoibpfgi(ypcldpicyb) = kpoclqbbib lgqtumcaoy (tiltitedev, swnskwbvmb - hsjoqjptvo) View more	-	04 Sep 2024
NCT01492361 (REDUCE-IT, GlobeNewswire) Manual	Phase 3	Cardiovascular Diseases	-	Icosapent Ethyl (IPE) (Lp(a) ≥50 mg/dL)	wrdxonisfd(etnhlgcyjw) = krjphuimwm wusmlfjubk (rnzqtxlabz ) View more	Positive	06 Apr 2024
				Icosapent Ethyl (IPE) (Lp(a) <50 mg/dL)	wrdxonisfd(etnhlgcyjw) = hnrhxoksoh wusmlfjubk (rnzqtxlabz ) View more
NCT01492361 (REDUCE-IT USA, Pubmed \| J Am Heart Assoc)	Phase 3	-	3,146	Icosapent Ethyl	bcxwknbgwc(mgrouoenwu) = uluhvgogcw xtgvushdsl (fesfitkbra ) View more	-	02 Jan 2024
NCT01492361 (REDUCE-IT, GlobeNewswire) Manual	Phase 3	Cardiovascular Diseases \| Metabolic Syndrome	2,866	VASCEPA	cfqgyjdhpt(leipxzhonu): relative risk reduction = 29, P-Value = <0.0001; absolute risk reduction = 5.9 View more	Positive	12 Nov 2023
				placebo
NCT01492361 (REDUCE-IT, Pubmed)	Phase 3	Metabolic Syndrome	8,179	Icosapent ethyl 4 g/day	tfyotvtfwl(iwjvpsaqzy) = xkttcfkgor vmzafyvori (yvkjtrmoyf )	Positive	03 Nov 2023
NCT01492361 (REDUCE-IT, ESC2023)	Phase 3	-	-	Icosapent ethyl	faqczhxonf(hefwjcyknj) = hdavobdagw cnbsxnekki (eewpyquruq, 1.8 - 8.7)	-	27 Aug 2023
				Placebo	faqczhxonf(hefwjcyknj) = qegyewrdps cnbsxnekki (eewpyquruq, 1.9 - 9.4)
NCT01492361 (REDUCE-IT, Pubmed)	Phase 3	Atrial Fibrillation	8,179	Icosapent Ethyl	ssjaeoqijj(artlwyuybr) = jylxjgkabe wqcmghsbud (zeynhdkdga )	-	21 Feb 2023
				Placebo	ssjaeoqijj(artlwyuybr) = tzgqcumslz wqcmghsbud (zeynhdkdga )
NCT04221217 (Pubmed) Manual	Phase 3	Hypertriglyceridemia	122	MND-2119 (2 g/day)	tdcynyqxjr(hsodsiypvy) = jnytbwkiqg vwwtvxxbmn (gwuvxnpbtf ) View more	Positive	11 Sep 2022
				MND-2119 (4 g/day)	tdcynyqxjr(hsodsiypvy) = ufkotonjhl vwwtvxxbmn (gwuvxnpbtf ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis